Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Sep 20, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The SHODBADI clinical trial is studying a new method for removing large stones from the bile duct, which can cause serious issues like pancreatitis or infections. Researchers are looking at how well this method works when doctors use a special technique to quickly open up the bile duct for just 30 to 60 seconds, right after they see a specific change on an imaging test. The main goals are to see how effectively the stones are removed and to monitor any potential side effects, such as bleeding or new stones forming.
To participate in this trial, you need to be over 18 years old and have a large bile duct stone that is more than 10 millimeters in size. However, if you've had certain types of surgery, have specific health conditions, or are pregnant, you may not be eligible. If you join the study, you can expect to receive the new treatment while being closely monitored for any issues during and after the procedure. This trial is currently recruiting participants and is open to individuals of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years
- • Common bile duct stone \>10mm diameter
- Exclusion Criteria:
- • Altered anatomy after surgery (B II, Roux-en-Y reconstruction)
- • Common bile duct cysts
- • Acute pancreatitis
- • Distal common bile duct stricture or tumor
- • Coagulation disorders
- • Ongoing coagulation medication
- • Pregnancy
- • Inability to give an informed consent
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Turku, , Finland
Patients applied
Trial Officials
Mia Rainio, Md, PhD
Study Director
Helsinki University Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials